Skip to main content

Table 2 Comparisons of demographic and clinical characteristics between the high-ASDAS and low-ASDAS groups

From: Low BASDAI score alone is not a good predictor of anti-tumor necrosis factor treatment efficacy in ankylosing spondylitis: a retrospective cohort study

 

High-ASDAS group

(n=45)

Low-ASDAS group

(n=71)

p-value

Age, years

35.0 (30.2–40.4)

33.1 (25.6–40.3)

0.222

Male sex,

40 (88.9)

69 (97.2)

0.068

Disease duration, years

11.1 (6.1–15.3)

9.8 (4.6–15.8)

0.465

Follow-up duration, years

6.4 (4.0–6.9)

6.5 (4.6–7.2)

0.289

HLA B27 positivity

44 (97.8)

71 (100)

0.207

Peripheral joint involvement

22 (48.9)

30 (42.3)

0.484

History of psoriasis

1 (2.2)

1 (1.4)

0.751

History of uveitis

13 (28.9)

22 (31.0)

0.811

mSASSS

12.0 (6.0–26.7)

8.0 (6.0–23.7)

0.256

BASDAI

3.0 ± 0.6

1.8 ± 0.8

< 0.001

ASDAS-CRP

2.5 ± 0.3

1.7 ± 0.2

< 0.001

ESR, mm/hr

5.0 (2.0–11.5)

2.0 (2.0–5.0)

0.003

 Abnormal ESR

7 (15.6)

2 (2.8)

0.012

CRP, mg/dL

0.2 (0.2–0.3)

0.2 (0.2–0.2)

0.243

 Abnormal CRP

8 (17.8)

1 (1.4)

0.001

Initial BASDAI (0 month)

6.7 ± 1.3 (n=45)

6.7 ± 1.5 (n=71)

0.768

Initial ASDAS-CRP (0 month)

3.9 ± 0.8 (n=35)

4.0 ± 1.0 (n=57)

0.471

Initial ESR (0 month), mm/hr

31.5 (17.8–55.0) (n=43)

38.0 (21.0–76.0) (n=70)

0.331

Initial CRP (0 month), mg/dL

1.6 (0.9–3.4) (n=43)

1.9 (0.2–4.7) (n=70)

0.562

Follow-up BASDAI (9 months)

2.9 ± 1.1 (n=45)

2.3 ± 1.4 (n=71)

0.007

Follow-up ASDAS-CRP (9 months)

1.8 ± 0.6 (n=36)

1.5 ± 0.7 (n=58)

0.079

 High ASDAS-CRP (9 months)

10 (27.8%)

8 (13.8%)

0.094

Follow-up ESR (9 months), mm/hr

5.0 (2.0–11.0) (n=39)

2.0 (2.0–7.0) (n=64)

0.299

Follow-up CRP (9 months), mg/dL

0.2 (0.2–0.2) (n=39)

0.2 (0.2–0.2) (n=65)

0.795

Discontinuation of anti-TNF agent

8 (17.8)

5 (7.1)

0.022

 Lack/loss of efficacy

7 (87.5)

2 (40)

 

 Clinical remission

0 (0)

3 (60)

 

 Adverse event

1 (12.5)

0 (0)

 
  1. Numerical quantitative data were presented as the “mean ± SD” or “median (IQR)” and categorical data were presented as the “frequency (%)”
  2. SD standard deviation, IQR interquartile range, HLA B27 human leukocyte antigen B27, mSASSS modified Stoke Ankylosing Spondylitis Spine Score, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, ASDAS Ankylosing Spondylitis Disease Activity Score, CRP C-reactive protein, ESR erythrocyte sedimentation rate, TNF Tumor necrosis factor